SynAct Pharma summarises busy second quarter
SynAct Pharma’s CEO Jeppe Øvlesen and CFO Patrik Renblad visit BioStock’s studio to talk about the second quarter report, the uplisting to Nasdaq Stockholm Main Market and the new design for the phase IIa study with AP1189 in idiopathic membranous nephropathy (iMN). In addition, we get to know more about the company’s main focus this fall and how long the current cash position will finance the development activities.
Watch the interview with SynAct Pharma‘s CEO Jeppe Øvlesen and CFO Patrik Renblad below.
